Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/977
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSILVA, L. C. R.-
dc.contributor.authorGELUK, A.-
dc.contributor.authorARNONE, M.-
dc.contributor.authorROMITI, R.-
dc.contributor.authorFRANKEN, K. C. L. M.-
dc.contributor.authorDUARTE, A. J. S.-
dc.contributor.authorTAKAHASHI, M. D. F.-
dc.contributor.authorBENARD, G.-
dc.date.accessioned2013-07-30T15:15:01Z-
dc.date.available2013-07-30T15:15:01Z-
dc.date.issued2012-
dc.identifier.citationJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.26, n.3, p.319-324, 2012-
dc.identifier.issn0926-9959-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/977-
dc.description.abstractBackground Infliximab and etarnecept are now widely used for treating severe psoriasis. However, these drugs, especially infliximab, increased the risk of tuberculosis reactivation. Surprisingly, epidemiological data suggest that the tuberculosis rate in patients taking infliximab in Sao Paulo State, Brazil, is similar to that of some developed, non-endemic countries. Objective The aim of this study was to better understand the effect of infliximab on Mycobacterium tuberculosis (Mtb) immune responses of psoriasis patients in an endemic setting (Brazil). Methods We evaluated the tuberculosis-specific immune responses of severe psoriasis patients and healthy individuals, both tuberculin skin test (TST) positive, in the presence/absence of infliximab. Patients had untreated severe psoriasis, no co-morbidities affecting the immune responses and a TST >10 mm. Healthy TST+ (>10 mm) individuals were evaluated in parallel. PBMC cultures from both groups were stimulated with different Mycobacterium tuberculosis (Mtb) antigens (ESAT-6, 85B and Mtb lysate) and phytohemagglutinin, with or without infliximab (5 mu g/mL). Parameters evaluated were TNF-alpha, IFN-gamma and IL-10 secretion by ELISA, overnight IFN-gamma ELISpot and lymphocyte proliferative response (LPR). Results Infliximab almost abolished TNF-alpha detection in PBMC supernatants of both groups. It also significantly reduced the LPR to phytohemagglutinin and the Mtb antigens as well as the IFN-gamma levels secreted into day 5 supernatants in both groups. There was no concomitant exaggerated IL-10 secretion that could account for the decreases in these responses. ELISpot showed that, contrasting with the central-memory responses above, infliximab did not affect effector-memory INF-gamma-releasing T-cell numbers. Conclusions Infliximab affected some, but not all aspects of the in vitro antituberculosis immune responses tested. The preserved effector-memory responses, putatively related to exposure to environmental mycobacteria, may help to explain the lower than expected susceptibility to tuberculosis reactivation in our setting. Received: 29 December 2010; Accepted: 9 March 2011-
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [05/57761-7, 05/60075-8]-
dc.description.sponsorshipNetherlands Leprosy Relief Foundation (NLR)-
dc.description.sponsorshipEuropean Commission-
dc.language.isoeng-
dc.publisherWILEY-BLACKWELL-
dc.relation.ispartofJournal of the European Academy of Dermatology and Venereology-
dc.rightsrestrictedAccess-
dc.subject.othertumor-necrosis-factor-
dc.subject.othermemory t-cells-
dc.subject.otherinterferon-gamma-
dc.subject.otherrheumatoid-arthritis-
dc.subject.otherlatent tuberculosis-
dc.subject.otherfactor antagonists-
dc.subject.otherfactor blockers-
dc.subject.otherinfection-
dc.subject.otherreactivation-
dc.subject.othereffector-
dc.titleInfliximab partially impairs the anti-Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin-test-
dc.typearticle-
dc.rights.holderCopyright WILEY-BLACKWELL-
dc.identifier.doi10.1111/j.1468-3083.2011.04067.x-
dc.identifier.pmid21623925-
dc.subject.wosDermatology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalGELUK, A.:Leiden Univ, Dept Infect Dis, Med Ctr, Leiden, Netherlands-
hcfmusp.author.externalFRANKEN, K. C. L. M.:Leiden Univ, Dept Infect Dis, Med Ctr, Leiden, Netherlands-
hcfmusp.description.beginpage319-
hcfmusp.description.endpage324-
hcfmusp.description.issue3-
hcfmusp.description.volume26-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000300676100008-
hcfmusp.origem.id2-s2.0-84857373462-
hcfmusp.publisher.cityMALDEN-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAgnholt J, 2003, CYTOKINE, V23, P76, DOI 10.1016/S1043-4666(03)00201-1-
hcfmusp.relation.referenceBruns H, 2009, J CLIN INVEST, V119, P1167, DOI 10.1172/JCI38482-
hcfmusp.relation.referenceCarmona L, 2005, ARTHRITIS RHEUM, V52, P1766, DOI 10.1002/art.21043-
hcfmusp.relation.referencede Leon DP, 2005, ANN RHEUM DIS, V64, P1360, DOI 10.1136/ard.2004.029041-
hcfmusp.relation.referenceDupuis S, 2000, IMMUNOL REV, V178, P129, DOI 10.1034/j.1600-065X.2000.17810.x-
hcfmusp.relation.referenceFranken KLMC, 2000, PROTEIN EXPRES PURIF, V18, P95, DOI 10.1006/prep.1999.1162-
hcfmusp.relation.referenceGodkin AJ, 2002, J IMMUNOL, V169, P2210-
hcfmusp.relation.referenceGomez-Reino JJ, 2003, ARTHRITIS RHEUM, V48, P2122, DOI 10.1002/art.11137-
hcfmusp.relation.referenceHamdi H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1994-
hcfmusp.relation.referenceHarris J, 2008, J INFECT DIS, V198, P1842, DOI 10.1086/593174-
hcfmusp.relation.referenceHenao-Tamayo MI, 2010, CLIN VACCINE IMMUNOL, V17, P618, DOI 10.1128/CVI.00368-09-
hcfmusp.relation.referenceJacobs M, 2007, MICROBES INFECT, V9, P623, DOI 10.1016/j.micinf.2007.02.002-
hcfmusp.relation.referenceLindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592-
hcfmusp.relation.referenceMendonca M, 2007, CLIN IMMUNOL, V125, P60, DOI 10.1016/j.clim.2007.06.002-
hcfmusp.relation.referenceOlsen AW, 2004, SCAND J IMMUNOL, V60, P273, DOI 10.1111/j.0300-9475.2004.01471.x-
hcfmusp.relation.referencePai Madhukar, 2006, J Occup Med Toxicol, V1, P7, DOI 10.1186/1745-6673-1-7-
hcfmusp.relation.referenceRoberts AD, 2005, J EXP MED, V202, P123, DOI 10.1084/jem.20050137-
hcfmusp.relation.referenceSaliu OY, 2006, J INFECT DIS, V194, P486, DOI 10.1086/505430-
hcfmusp.relation.referenceSichletidis L, 2006, INT J TUBERC LUNG D, V10, P1127-
hcfmusp.relation.referenceSilva LCR, 2010, ARCH DERMATOL RES, V302, P255, DOI 10.1007/s00403-009-0982-2-
hcfmusp.relation.referenceSmieja M, 2000, COCHRANE DB SYST REV, V2, DOI 10.1002/14651858.CD001363-
hcfmusp.relation.referenceSt Clair E William, 2002, Arthritis Rheum, V46, P1451, DOI 10.1002/art.10302-
hcfmusp.relation.referenceTubach F, 2009, ARTHRITIS RHEUM, V60, P1884, DOI 10.1002/art.24632-
hcfmusp.relation.referenceUeki SYM, 2005, REV BRAS PATOL MED L, V41, P1-
hcfmusp.relation.referenceWallis RS, 2007, J INVEST DERM SYMP P, V12, P16, DOI 10.1038/sj.jidsymp.5650031-
hcfmusp.relation.referenceWallis RS, 2005, CLIN INFECT DIS S3, V41, P194, DOI 10.1086/429996-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipEuropean Union-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus3-
hcfmusp.scopus.lastupdate2024-04-12-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDT
Departamento de Dermatologia - FM/MDT

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/03
LIM/03 - Laboratório de Medicina Laboratorial

Artigos e Materiais de Revistas Científicas - LIM/56
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências


Files in This Item:
File Description SizeFormat 
art_SILVA_Infliximab_partially_impairs_the_anti_Mycobacterium_tuberculosis_immune_2012.PDF
  Restricted Access
publishedVersion (English)200.26 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.